Advertisement

Hypertension and Prevention of Diastolic Heart Failure in the Aging Population

  • Wilbert S. AronowEmail author
  • Maciej Banach
  • Ali Ahmed
Chapter

Abstract

In older Americans, hypertension is the most important risk factor for cardiovascular disease (CVD) and is present in 74 % of patients with incident heart failure (HF). The prevalence of a normal left ventricular (LV) ejection fraction (EF) associated with HF or diastolic HF (DHF) increases with age, is higher in older women than in older men, and is present in approximately half of older HF patients. Hypertension is more common in patients with DHF than in systolic HF or HF with a low LVEF. In older adults with hypertension, LV diastolic dysfunction leads more often to HF than does LV systolic dysfunction. Hypertension can progress to HF through different pathways. These include development of LV hypertrophy, impaired LV filling, and increased wall thickness. DHF in older adults is probably related to progressive fibrosis and myocardial stiffening associated with age, hypertension, LV hypertrophy, coronary artery disease, and diabetes mellitus. This chapter will discuss LV diastolic dysfunction, LV hypertrophy, prevention of HF by antihypertensive drug therapy in older adults, DHF, and prevention and treatment of DHF in older adults with hypertension.

Keywords

Left Ventricular Hypertrophy Left Ventricular Mass Left Ventricular Mass Index Left Ventricular Diastolic Dysfunction Diastolic Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220.PubMedCrossRefGoogle Scholar
  2. 2.
    Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123(21):2434–506.PubMedCrossRefGoogle Scholar
  3. 3.
    Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Ekundayo OJ, Allman RM, Sanders PW, Aban I, Love TE, Arnett D, et al. Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension. 2009;53(3):458–65.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Iyer AS, Ahmed MI, Filippatos GS, Ekundayo OJ, Aban IB, Love TE, et al. Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010;4(1):22–31.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Redfield MM, Jacobsen SJ, Burnett Jr JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202.PubMedCrossRefGoogle Scholar
  7. 7.
    Perry GJ, Ahmed MI, Desai RV, Mujib M, Zile M, Sui X, et al. Left ventricular diastolic function and exercise capacity in community-dwelling adults ≥65 years of age without heart failure. Am J Cardiol. 2011;108(5):735–40.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998;113(4):867–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and Whites. Am J Cardiol. 1999;84(5):611–2. A619.PubMedCrossRefGoogle Scholar
  10. 10.
    Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33(7):1948–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137(8):631–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Ahmed A. Association of diastolic dysfunction and outcomes in ambulatory older adults with chronic heart failure. J Gerontol A Biol Sci Med Sci. 2005;60(10):1339–44.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Lakatta EG. Mechanisms of hypertension in the elderly. J Am Geriatr Soc. 1989;37(8):780–90.PubMedGoogle Scholar
  15. 15.
    Guichard JL, Desai RV, Ahmed MI, Mujib M, Fonarow GC, Feller MA, et al. Isolated diastolic hypotension and incident heart failure in older adults. Hypertension. 2011;58(5):895–901.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Gribbin B, Pickering TG, Sleight P, Peto R. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res. 1971;29(4):424–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Aronow WS. Dizziness and syncope. In: Hazzard WR, Blass JP, Ettinger WHJ, Halter JB, Ouslander JG, editors. Principles of geriatric medicine and gerontology. 4th ed. New York, NY: McGraw-Hill; 1998. p. 1519–34.Google Scholar
  18. 18.
    Joseph J, Koka M, Aronow WS. Prevalence of moderate and severe renal insufficiency in older persons with hypertension, diabetes mellitus, coronary artery disease, peripheral arterial disease, ischemic stroke, or congestive heart failure in an academic nursing home. J Am Med Dir Assoc. 2008;9(4):257–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Chiong JR, Aronow WS, Khan IA, Nair CK, Vijayaraghavan K, Dart RA, et al. Secondary hypertension: current diagnosis and treatment. Int J Cardiol. 2008;124(1):6–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. 2012;308(9):875–81.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Mukherjee D. Atherogenic vascular stiffness and hypertension: cause or effect? JAMA. 2012;308(9):919–20.PubMedCrossRefGoogle Scholar
  22. 22.
    Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol. 2011;57(14):1511–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail. 2011;13(10):1087–95.PubMedCrossRefGoogle Scholar
  24. 24.
    Iriarte MM, Perez Olea J, Sagastagoitia D, Molinero E, Murga N. Congestive heart failure due to hypertensive ventricular diastolic dysfunction. Am J Cardiol. 1995;76(13):43D–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Rosei EA. Clinical value of diastolic dysfunction in hypertension. J Hypertens. 2002;20(6):1083–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Kato S, Onishi K, Yamanaka T, Takamura T, Dohi K, Yamada N, et al. Exaggerated hypertensive response to exercise in patients with diastolic heart failure. Hypertens Res. 2008;31(4):679–84.PubMedCrossRefGoogle Scholar
  27. 27.
    Fujimoto N, Onishi K, Dohi K, Tanabe M, Kurita T, Takamura T, et al. Hemodynamic characteristics of patients with diastolic heart failure and hypertension. Hypertens Res. 2008;31(9):1727–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Sharp A, Tapp R, Francis DP, Mc GTSA, Hughes AD, Stanton AV, et al. Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. J Am Coll Cardiol. 2008;52(12):1015–21.PubMedCrossRefGoogle Scholar
  29. 29.
    Lalande S, Johnson BD. Diastolic dysfunction: a link between hypertension and heart failure. Drugs Today (Barc). 2008;44(7):503–13.CrossRefGoogle Scholar
  30. 30.
    Chang SA, Kim HK, Kim DH, Kim YJ, Sohn DW, Oh BH, et al. Left ventricular systolic and diastolic dyssynchrony in asymptomatic hypertensive patients. J Am Soc Echocardiogr. 2009;22(4):337–42.PubMedCrossRefGoogle Scholar
  31. 31.
    Gradman AH, Wilson JT. Hypertension and diastolic heart failure. Curr Cardiol Rep. 2009;11(6):422–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Verma A, Solomon SD. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am. 2009;93(3):647–64.PubMedCrossRefGoogle Scholar
  33. 33.
    Volpe M, McKelvie R, Drexler H. Hypertension as an underlying factor in heart failure with preserved ejection fraction. J Clin Hypertens (Greenwich). 2010;12(4):277–83.CrossRefGoogle Scholar
  34. 34.
    Wachtell K, Palmieri V, Gerdts E, Bella JN, Aurigemma GP, Papademetriou V, et al. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). Am J Cardiol. 2010;106(7):999–1005.PubMedCrossRefGoogle Scholar
  35. 35.
    Masugata H, Senda S, Murao K, Inukai M, Hosomi N, Iwado Y, et al. Visit-to-visit variability in blood pressure over a 1-year period is a marker of left ventricular diastolic dysfunction in treated hypertensive patients. Hypertens Res. 2011;34(7):846–50.PubMedCrossRefGoogle Scholar
  36. 36.
    Zanchetti A, Cuspidi C, Comarella L, Rosei EA, Ambrosioni E, Chiariello M, et al. Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-diadys study. J Hypertens. 2007;25(10):2158–67.PubMedCrossRefGoogle Scholar
  37. 37.
    Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 1996;156(16):1789–96.PubMedCrossRefGoogle Scholar
  38. 38.
    Deedwania PC. The progression from hypertension to heart failure. Am J Hypertens. 1997;10(10 Pt 2):280S–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123(3):327–34.PubMedCrossRefGoogle Scholar
  40. 40.
    Douglas PS, Katz SE, Weinberg EO, Chen MH, Bishop SP, Lorell BH. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol. 1998;32(4):1118–25.PubMedCrossRefGoogle Scholar
  41. 41.
    Bella JN, Palmieri V, Kitzman DW, Liu JE, Oberman A, Hunt SC, et al. Gender difference in diastolic function in hypertension (the HyperGEN study). Am J Cardiol. 2002;89(9):1052–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Muller-Brunotte R, Kahan T, Lopez B, Edner M, Gonzalez A, Diez J, et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens. 2007;25(9):1958–66.PubMedCrossRefGoogle Scholar
  43. 43.
    Aronow WS, Ahn C, Kronzon I, Koenigsberg M. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol. 1991;67(4):295–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Aronow WS. Left ventricular hypertrophy. J Am Geriatr Soc. 1992;40(1):71–80.PubMedGoogle Scholar
  45. 45.
    Desai RV, Ahmed MI, Mujib M, Aban IB, Zile MR, Ahmed A. Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. Am J Cardiol. 2011;107(2):321–4.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Devereux RB, Pickering TG, Harshfield GA, Kleinert HD, Denby L, Clark L, et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation. 1983;68(3):470–6.PubMedCrossRefGoogle Scholar
  47. 47.
    de Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J. 2008;29(6):741–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Aronow WS, Ahn C. Association of electrocardiographic left ventricular hypertrophy with the incidence of new congestive heart failure. J Am Geriatr Soc. 1998;46(10):1280–1.PubMedGoogle Scholar
  49. 49.
    Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med. 2007;147(5):311–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369(9579):2079–87.PubMedCrossRefGoogle Scholar
  51. 51.
    Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlof B, et al. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE Study. Am J Hypertens. 2012;25(10):1101–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Drayer JIM, Gardin JM, Weber MA, Aronow WS. Changes in cardiac anatomy and function during therapy with alpha-methyldopa: an echocardiographic study. Curr Ther Res. 1982;32:856–65.Google Scholar
  53. 53.
    Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5(2):95–110.PubMedGoogle Scholar
  54. 54.
    Drayer JI, Gardin JM, Weber MA, Aronow WS. Cardiac muscle mass during vasodilation therapy of hypertension. Clin Pharmacol Ther. 1983;33(6):727–32.PubMedCrossRefGoogle Scholar
  55. 55.
    Julien J, Dufloux MA, Prasquier R, Chatellier G, Menard D, Plouin PF, et al. Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison. J Am Coll Cardiol. 1990;16(1):137–42.PubMedCrossRefGoogle Scholar
  56. 56.
    Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1(8442):1349–54.PubMedCrossRefGoogle Scholar
  57. 57.
    Kostis JB, Davis BR, Cutler J, Grimm Jr RH, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278(3):212–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.PubMedCrossRefGoogle Scholar
  59. 59.
    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2011;8(1):13–28.PubMedCrossRefGoogle Scholar
  61. 61.
    Aronow WS. Hypertension guidelines. Hypertension. 2011;58(3):347–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Banach M, Michalska M, Kjeldsen SE, Malyszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011;12(12):1835–44.PubMedCrossRefGoogle Scholar
  63. 63.
    Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients? ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn. 2011;121(7–8):253–7.PubMedGoogle Scholar
  64. 64.
    Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press. 2012;21(1):3–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Banach M, Aronow WS. Hypertension therapy in the older adults-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens. 2012;26(11):641–3.PubMedCrossRefGoogle Scholar
  66. 66.
    Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107(8):1208–14.PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115(15):1982–90.PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Zhang Y, Kilgore ML, Arora T, Mujib M, Ekundayo OJ, Aban IB, et al. Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data. Int J Cardiol. 2013;166(1):230–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011;124(23):2491–501.PubMedCrossRefGoogle Scholar
  70. 70.
    Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol. 2007;49(9):972–81.PubMedCrossRefGoogle Scholar
  71. 71.
    Zile MR, Lewinter MM. Left ventricular end-diastolic volume is normal in patients with heart failure and a normal ejection fraction: a renewed consensus in diastolic heart failure. J Am Coll Cardiol. 2007;49(9):982–5.PubMedCrossRefGoogle Scholar
  72. 72.
    Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998–1005.PubMedCrossRefGoogle Scholar
  73. 73.
    Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344(1):17–22.PubMedCrossRefGoogle Scholar
  74. 74.
    Margulescu AD, Rimbas RC, Florescu M, Dulgheru RE, Cinteza M, Vinereanu D. Cardiac adaptation in acute hypertensive pulmonary edema. Am J Cardiol. 2012;109(10):1472–81.PubMedCrossRefGoogle Scholar
  75. 75.
    Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008;117(16):2051–60.PubMedCrossRefGoogle Scholar
  76. 76.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479.PubMedCrossRefGoogle Scholar
  77. 77.
    Frohlich ED, Susic D. Sodium and its multiorgan targets. Circulation. 2011;124(17):1882–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Webster JL, Dunford EK, Hawkes C, Neal BC. Salt reduction initiatives around the world. J Hypertens. 2011;29(6):1043–50.PubMedCrossRefGoogle Scholar
  79. 79.
    Aronow WS, Ahn C, Kronzon I, Nanna M. Prognosis of congestive heart failure in patients aged > or =62 years with unoperated severe valvular aortic stenosis. Am J Cardiol. 1993;72(11):846–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Aronow WS, Ahn C, Kronzon I, Nanna M. Prognosis of patients with heart failure and unoperated severe aortic valvular regurgitation and relation to ejection fraction. Am J Cardiol. 1994;74(3):286–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Alagiakrishnan K, Banach M, Jones LG, Datta S, Ahmed A, Aronow WS. Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. Ann Med. 2013;45(1):37–50.PubMedCrossRefGoogle Scholar
  82. 82.
    Haykowsky MJ, Brubaker PH, Stewart KP, Morgan TM, Eggebeen J, Kitzman DW. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. J Am Coll Cardiol. 2012;60(2):120–8.PubMedCentralPubMedCrossRefGoogle Scholar
  83. 83.
    Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or =40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;80(2):207–9.PubMedCrossRefGoogle Scholar
  84. 84.
    van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure). J Am Coll Cardiol. 2009;53(23):2150–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol. 1993;71(7):602–4.PubMedCrossRefGoogle Scholar
  86. 86.
    Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.PubMedCrossRefGoogle Scholar
  87. 87.
    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.PubMedCrossRefGoogle Scholar
  88. 88.
    Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.PubMedCrossRefGoogle Scholar
  89. 89.
    Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, et al. Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail. 2012;14(10):1179–88.PubMedCrossRefGoogle Scholar
  90. 90.
    Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail. 2011;17(8):634–42.PubMedCrossRefGoogle Scholar
  92. 92.
    Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, et al. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2013;1(1):40–7.PubMedCentralPubMedCrossRefGoogle Scholar
  93. 93.
    Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011;162(6):966–72.e910.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Wilbert S. Aronow
    • 1
    • 2
    Email author
  • Maciej Banach
    • 3
  • Ali Ahmed
    • 4
    • 5
  1. 1.Department of MedicineWestchester Medical Center/New York Medical CollegeValhallaUSA
  2. 2.Cardiology DivisionNew York Medical CollegeValhallaUSA
  3. 3.Department of HypertensionMedical University of LodzLodzPoland
  4. 4.Department of MedicineUniversity of Alabama School of Medicine at BirminghamBirminghamUSA
  5. 5.Department of MedicineVeterans Affairs Medical CenterBirminghamUSA

Personalised recommendations